Drug Approval | January 24, 2026
Sun Pharma gets DCGI nod to launch generic Semaglutide injection for weight loss in India
Company to launch product after the expiry of semaglutide patent in India
Company to launch product after the expiry of semaglutide patent in India
This innovation enhances viral stability, preserves potency, and reduces allergic reactions and antigen crystallisation-related issues
Gastrointestinal conditions affect millions across the UK, yet research in the field has often been fragmented, slow, or under-resourced
The collaboration will focus on enhancing surgeon capabilities, developing structured training pathways, and promoting the adoption of robotic-assisted surgery in both routine and complex procedures
Myqorzo, a selective small-molecule cardiac myosin inhibitor, is designed to improve functional capacity and relieve symptoms in oHCM
Waskyra is an ex vivo gene therapy that uses patients’ own CD34+ hematopoietic stem and progenitor cells, genetically engineered with a lentiviral vector
Favorable outcome would contribute to significantly containing the Roundup litigation as the company continues its multi-pronged strategy
The therapy is mutation-agnostic and aims to overcome limitations of existing EGFR-targeting drugs by concentrating degradation in tumors while sparing healthy tissue
DME is among the most challenging retinal diseases to treat and has long served as a proving ground for therapies that ultimately become first-line standard of care in retinal diseases
The approval is backed by data showing deep, durable responses and manageable tolerability
Subscribe To Our Newsletter & Stay Updated
